ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com



Ò½ÏßÒ©ÎÅ1. 3ÔÂ6ÈÕ£¬£¬£¬£¬£¬ÐÂÑ¿»ùÒòÐû²¼ÆäÓÃÓÚÖÎÁÆDMDµÄÈ«ÇòÊ×´´ÐÔ»ùÒò±à¼Ò©ÎïGEN6050XµÄINDÉêÇëÒÑ»ñFDAÅú×¼¡£¡£¡£GEN6050X×¢ÉäÒºÊÇÒ»ÖÖʹÓÃË«AAV9ÔØÌåµÄ¾²Âö×¢Éä°ûà×़î»ù±à¼Ò©Î£¬£¬£¬£¬×¨ÎªÊʺÏÍâÏÔ×Ó50ÌøÔ¾µÄDMD»¼ÕßÉè¼Æ¡£¡£¡£
2. 3ÔÂ6ÈÕ£¬£¬£¬£¬£¬ÑÇÊ¢Ò½Ò©Ðû²¼µÚÈý´úBCR-ABLÒÖÖÆ¼Á°ÂÀ×°ÍÌæÄᣨÉÌÆ·Ãû£ºÄÍÁ¢¿Ë£©»ñCDEÄÉÈë¡±Í»ÆÆÐÔÖÎÁÆÆ·ÖÖ¡±Ãûµ¥£¬£¬£¬£¬£¬Ë³Ó¦Ö¢Îª£ºÁªºÏ»¯ÁÆÒ»ÏßÖÎÁÆÐÂÕï¶Ï·Ñ³ÇȾɫÌåÑôÐÔ£¨Ph+£©¼±ÐÔÁܰÍϸ°û°×Ѫ²¡£¡£¡£¨ALL£©»¼Õߣ¬£¬£¬£¬£¬´Ë˳Ӧ֢ÓÚ2023Äê7Ô»ñCDEÅú×¼ÁÙ´²ÊÔÑéÔÊÐí¡£¡£¡£
3. 3ÔÂ6ÈÕ£¬£¬£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬£¬Åµ»ª£¨Novartis£©É걨µÄ1ÀàÐÂÒ©ÈðÃײ¼ÌæÄáÆ¬µÄÉÏÊÐÉêÇëÄâÄÉÈëÓÅÏÈÉóÆÀ£¬£¬£¬£¬£¬ÊÊÓÃÓÚH1¿¹×é°·Ò©ÖÎÁƺóÈÔÓÐÖ¢×´µÄ³ÉÈËÂýÐÔ×Ô¾õÐÔÝ¡ÂéÕCSU£©»¼Õß¡£¡£¡£
4. 3ÔÂ6ÈÕ£¬£¬£¬£¬£¬ºãÈðÒ½Ò©Ðû²¼Í¨¸æ³Æ£¬£¬£¬£¬£¬¿ËÈÕ£¬£¬£¬£¬£¬¹«Ë¾×Ó¹«Ë¾ËÕÖÝÊ¢µÏÑÇÉúÎïÒ½Ò©ÓÐÏÞ¹«Ë¾¡¢ÉϺ£Ê¢µÏÒ½Ò©ÓÐÏÞ¹«Ë¾ÊÕµ½¹ú¼ÒÒ©¼à¾ÖÅú׼ǩ·¢µÄ¡¶Ò©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡·£¬£¬£¬£¬£¬Åú×¼×¢ÉäÓÃSHR-A1811¡¢±´·¥Öéµ¥¿¹×¢ÉäÒº¡¢°¢µÃ±´Àûµ¥¿¹×¢ÉäÒº¡¢SHR-8068×¢ÉäÒº¿ªÕ¹ÁÙ´²ÊÔÑé¡£¡£¡£ÏêϸΪעÉäÓÃSHR-A1811ÁªºÏ¼Æ»®ÖÎÁÆÍíÆÚʵÌåÖ×ÁöµÄ¿ª·Å¡¢¶àÖÐÐÄIb/¢òÆÚÁÙ´²Ñо¿¡£¡£¡£
1. 3ÔÂ4ÈÕ£¬£¬£¬£¬£¬³¤·çÒ©ÒµÓ뻪Èó°²»ÕÒ½Ò©¾ÙÐÐ̸Åв¢Ç©ÊðÕ½ÂÔÏàÖúÐÒé¡£¡£¡£³¤·çҩҵʼÖÕרעÓÚÁ¢ÒìÒ©ÎïµÄÑз¢ÓëÉú²ú£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚ³ÉΪÖйúºôÎüÁìÓòµÄÁìÏÈÕߣ¬£¬£¬£¬£¬Æä²úÆ·ÁýÕÖÏø´¡¢ÂýÐÔÛÕ±ÕÐԷβ¡£¡£¡£¨COPD£©¡¢¹ýÃôÐÔ±ÇÑס¢·ÎÏËά»¯¡¢·Î¶¯Âö¸ßѹµÈ¶à¸öºôÎüϵͳ¼²²¡ÁìÓò¡£¡£¡£
1. 3ÔÂ6ÈÕ£¬£¬£¬£¬£¬È«Çò¶¥¼¶ÆÚ¿¯ ¡¶Nature Medicine¡·£¨IF:58.7£© ¸Õ¸Õ½ÒÏþÁËÒ»ÏîÍ»ÆÆÐÔÑо¿£¬£¬£¬£¬£¬Ê×´ÎÃ÷È·Õ¹ÏÖÁËÃâÒßÁÆ·¨ÖÎÁư¢¶û´Äº£Ä¬²¡µÄÒªº¦»úÖÆ£¬£¬£¬£¬£¬ÉîÈëÚ¹ÊÍÁËÃâÒßÁÆ·¨ÎªºÎÄÜÓÐÓÃɨ³ýÄÔÄÚµí·ÛÑùÂѰף¨A¦Â£©¡£¡£¡£
[1] van Olst, L., Simonton, B., Edwards, A.J. et al. Microglial mechanisms drive amyloid-¦Â clearance in immunized patients with Alzheimer¡¯s disease. Nat Med (2025). https://doi.org/10.1038/s41591-025-03574-1
Ïà¹ØÐÂÎÅ